Michael Benkowitz, President and COO of United Therapeutics Corp (NASDAQ:UTHR), recently executed a series of stock transactions, according to a recent SEC filing. On February 3, Benkowitz sold shares ...

UBS lowered the firm’s price target on United Therapeutics (UTHR) to $460 from $475 and keeps a Buy rating on the shares. United Therapeutics ...

United Therapeutics Corp. operates as a biotechnology company, which engages in the development and commercialization of unique products to address the unmet medical needs of patients with chronic ...

In this article, we are going to take a look at where United Therapeutics Corporation (NASDAQ ... development lasting more than ten years, the industry has a high failure rate.

The stock currently has a Zacks Rank #2 (Buy). Breaking things down more, United Therapeutics is a member of the Medical - Drugs industry, which includes 161 individual companies and currently ...

At ATS, United Therapeutics will host an educational industry theater on implementing treprostinil induction strategies in pulmonary hypertension, and the SILVER SPRING, Md. & RESEARCH TRIANGLE ...

United Therapeutics said the FDA has cleared it to begin the first clinical trial testing whether organs from gene-edited ...

Silver Spring’s United Therapeutics has scored a regulatory green light to start clinical trials for its genetically modified pig kidneys to be transplanted into humans. It's as significant for the ...

Strength Seen in Foghorn Therapeutics: Can Its 9.5% Jump Turn into More Strength? Foghorn Therapeutics Inc. (NASDAQ: FHTX) shares rallied 9.5% in the last trading session to close at $9.72.